Cautious optimism reigns for Isis SMA drug
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals chairman and CEO Stanley Crooke said on 21 March that investors should be cautiously optimistic about seemingly positive Phase I data for the antisense drug ISIS-SMNRx for the treatment of spinal muscular atrophy (SMA), and they heeded his advice by sending the Carlsbad-based company's stock price only mildly higher.